Phase 3 N=75 Intranasal Dexmedetomidine Premedication in Children
Preoperative Sedation
Primary: University of Michigan Sedation Scale — 15; 25; 22; 11 Participants — p=0.025
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=200 A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb
Osteoarthritis
Primary: Pain Visual Analogue Scale (VAS) — 57.1; 63.2; 60.7; 42.9 Units on a scale
Phase 3 N=543 Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Renal Transplantation
Primary: Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant — 85.9; 88.0; 84.8 percentage of participants
Phase 3 N=93 Long Term Chamomile Therapy for Anxiety
Generalized Anxiety Disorder
Primary: Time to Relapse in Each Treatment Condition. — 11.4; 6.3 weeks
Phase 3 N=41 Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children
Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety — 5; 5; 6; 20 Participants
Phase 3 N=422 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Psoriatic Arthritis
Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 — 50.47; 60.58; 51.89; 33.33 Percentage or participants…
Phase 3 N=385 Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children
Acellular Pertussis · Poliomyelitis · Tetanus
Primary: Number of Subjects With a Booster Response to Diphtheria (D) and Tetanus (T) Antigens — 176; 90; 173; 90 Participants
Phase 3 N=865 Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Subjects With a Vaccine Response for Anti-gE Antibodies — 394 Participants
Phase 3 N=1,225 A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died: PP-ITT — 70.1; 63.8 Percentage of Participants
Phase 3 N=1,445 Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease, Autosomal Dominant
Primary: Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 — 2.777; 5.608 Percentage change per year — p=<0.0001
Phase 3 N=398 Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking · Pulmonary Disease, Chronic Obstructive · Tobacco Use Disorder
Primary: Smoking Abstinence (Point Prevalent) — 23; 24 Participants — p=0.88
Phase 3 N=240 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 98.9; 100.0; 89.1; 95.2 Percentage of Participants
Phase 3 N=120 Pediatric Tonsillectomy Pain Reduction Study
Postoperative Pain
Primary: Total Number of Post-operative Doses of Analgesics. — 12; 12; 14 number of doses
Phase 3 N=500 Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
Intraventricular Hemorrhage
Primary: Participants With Modified Rankin Scale (mRS) <=3 - Dichotomized Analysis — 47.6; 44.9 percentage of participants — p=0.554
Phase 3 N=6 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg